Neuberger Berman Group LLC Increases Holdings in Emergent Biosolutions Inc (NYSE:EBS)

Share on StockTwits

Neuberger Berman Group LLC grew its holdings in shares of Emergent Biosolutions Inc (NYSE:EBS) by 27.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,988,473 shares of the biopharmaceutical company’s stock after buying an additional 635,676 shares during the quarter. Neuberger Berman Group LLC owned 0.06% of Emergent Biosolutions worth $236,120,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Handelsbanken Fonder AB purchased a new stake in shares of Emergent Biosolutions during the 2nd quarter valued at about $610,000. Nuveen Asset Management LLC raised its position in shares of Emergent Biosolutions by 6.3% during the 2nd quarter. Nuveen Asset Management LLC now owns 283,482 shares of the biopharmaceutical company’s stock valued at $22,418,000 after buying an additional 16,686 shares in the last quarter. WCM Investment Management LLC raised its position in shares of Emergent Biosolutions by 6.2% during the 2nd quarter. WCM Investment Management LLC now owns 105,261 shares of the biopharmaceutical company’s stock valued at $8,324,000 after buying an additional 6,165 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Emergent Biosolutions by 1.4% during the 2nd quarter. AQR Capital Management LLC now owns 73,831 shares of the biopharmaceutical company’s stock valued at $5,839,000 after buying an additional 1,006 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in Emergent Biosolutions by 11.2% during the 2nd quarter. Sei Investments Co. now owns 30,009 shares of the biopharmaceutical company’s stock valued at $2,379,000 after purchasing an additional 3,034 shares during the last quarter.

Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating and set a $89.00 price target on the stock. in a report on Wednesday, May 27th. Chardan Capital upped their price target on shares of Emergent Biosolutions from $86.00 to $112.00 and gave the company a “buy” rating in a report on Friday, July 31st. Cantor Fitzgerald upped their price target on shares of Emergent Biosolutions from $85.00 to $110.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Guggenheim dropped their target price on shares of Emergent Biosolutions from $101.00 to $87.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Finally, JPMorgan Chase & Co. began coverage on shares of Emergent Biosolutions in a research note on Monday. They issued a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $92.57.

In other Emergent Biosolutions news, Director Zsolt Harsanyi sold 6,609 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $133.71, for a total value of $883,689.39. Following the completion of the transaction, the director now owns 24,579 shares of the company’s stock, valued at $3,286,458.09. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Fuad El-Hibri sold 40,000 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $102.73, for a total transaction of $4,109,200.00. Following the completion of the transaction, the insider now directly owns 1,209,523 shares of the company’s stock, valued at approximately $124,254,297.79. The disclosure for this sale can be found here. Insiders have sold 81,027 shares of company stock valued at $8,898,199 in the last three months. 14.10% of the stock is currently owned by corporate insiders.

Shares of NYSE EBS traded down $0.18 during midday trading on Wednesday, reaching $102.58. 12,568 shares of the company’s stock traded hands, compared to its average volume of 658,993. The company has a quick ratio of 1.91, a current ratio of 2.71 and a debt-to-equity ratio of 0.63. The stock’s 50 day simple moving average is $115.00 and its 200-day simple moving average is $83.70. Emergent Biosolutions Inc has a one year low of $46.37 and a one year high of $137.61. The company has a market cap of $5.44 billion, a price-to-earnings ratio of 32.01 and a beta of 1.42.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.98 EPS for the quarter, beating the Zacks’ consensus estimate of $0.53 by $1.45. Emergent Biosolutions had a net margin of 13.52% and a return on equity of 22.92%. The company had revenue of $394.70 million during the quarter. Equities analysts predict that Emergent Biosolutions Inc will post 6.67 EPS for the current fiscal year.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Further Reading: Are sell-side analysts objective?

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply